Parcom Capital buys Viroclinics

Parcom Capital said Aug. 29 that it has acquired Viroclinics Biosciences. Financial terms weren’t announced. Viroclinics, of the Netherlands, tests new vaccines and drugs in the clinical trial stages prior to their market launch.

DealsNorth AmericaUSBriefs